Duke Cancer Institute study finds blood test could guide treatment for kidney cancer
A common enzyme that is easily detected in blood may predict how well patients with advanced kidney cancer will respond to a specific treatment, according to doctors at Duke Cancer Institute. The finding, published online Monday, Aug. 13, 2012, in the Journal of Clinical Oncology, could lead to the first blood test to determine the best treatment for late-stage kidney cancer.
Among the research institutions NCI funds across the United States, it currently designates 67 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.
This text may be reproduced or reused freely. Please credit the National Cancer Institute as the source. Any graphics may be owned by the artist or publisher who created them, and permission may be needed for their reuse.